Enhancing atrial‐specific gene expression using a calsequestrin cis‐regulatory module 4 with a sarcolipin promoter
Abstract
Cardiac gene therapy using the adeno‐associated virus serotype 9 vector is widely used because of its efficient transduction. However, the promoters used to drive expression often cause off‐target localization. To overcome this, studies have applied cardiac‐specific promoters, although expression is debilitated compared to that of ubiquitous promoters. To address these issues in the context of atrial‐specific gene expression, an enhancer calsequestrin cis‐regulatory module 4 (CRM4) and the highly atrial‐specific promoter sarcolipin were combined to enhance expression and minimize off tissue expression.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2018
- Source ID
- 10.1002/jgm.3060
Entities
People
- Dongtak Jeong
- Erik Kohlbrenner
- Jimeen Yoo
- Okkil Kim
- Roger J. Hajjar
Organizations
- Congressionally Directed Medical Research Programs
- Foundation for the National Institutes of Health
- Icahn School of Medicine at Mount Sinai
- National Institutes of Health
- United States Department of Defense